The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects.

QY201 is a dual inhibitor targeting Janus Kinase 1/Tyrosine Kinase 2, developed for the treatment of atopic dermatitis and other autoimmune diseases. The pharmacokinetics (PK), pharmacodynamics (PD), tolerability, and safety of QY201 were assessed in a randomized, double‐blind study in healthy subje...

Full description

Bibliographic Details

Published in:	Journal of Clinical Pharmacology Vol. 65; no. 11; pp. 1474 - 1485
Main Authors:	Wang, Jia‐ying, Gao, Ying‐hui, Ruan, Zou‐rong, Yang, Dan‐dan, Li, Hua, Qiao, Shi‐da, Li, Jian‐hui, You, Xin, Shi, Jun, Jiang, Bo
Format:	research tables/charts randomized controlled trial Journal Article
Published:	Wiley-Blackwell Nov2025
Online Access:	View this record in EBSCOhost